*According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as measured by a blinded independent central review committee.
†Assessed by independent central review committee.
‡Absence of significant clinical deterioration was defined as no new or worsening symptoms, no change in performance status for > 2 weeks, and no need for salvage therapy.
References: 1. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, openlabel, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385. 2. ClinicalTrials.gov. https://clinicaltrials.gov/ct2 resultscond=merkel+cell+carcinoma&term=immune&cntryl=&state1=&recrs=#wrapper. Accessed May 3, 2021.